BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 14.2] [Reference Citation Analysis]
2 Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46:3540-8. [PMID: 33864107 DOI: 10.1007/s00261-021-03074-z] [Reference Citation Analysis]
3 Chen L, Yu CX, Zhong BY, Zhu HD, Jin ZC, Zhu GY, Zhang Q, Ni CF, Teng GJ. Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:615133. [PMID: 33981722 DOI: 10.3389/fmolb.2021.615133] [Reference Citation Analysis]
4 Villani R, Cavallone F, Sangineto M, Fioravanti G, Romano AD, Serviddio G. Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy? Int J Clin Pract 2021;75:e13733. [PMID: 32981175 DOI: 10.1111/ijcp.13733] [Reference Citation Analysis]
5 Hasdemir DB, Dávila LA, Schweitzer N, Meyer BC, Koch A, Vogel A, Wacker F, Rodt T. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol 2017;23:217-22. [PMID: 28256449 DOI: 10.5152/dir.2016.16006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Nam JY, Choe AR, Sinn DH, Lee JH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Lee JM, Chung JW, Choi SY, Lee JK, Baek SY, Lee HA, Kim TH, Yoo K. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:504. [PMID: 32487089 DOI: 10.1186/s12885-020-06975-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
9 Matsuda N, Imai N, Kuzuya T, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Fujishiro M. Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma. In Vivo 2021;35:1185-9. [PMID: 33622919 DOI: 10.21873/invivo.12367] [Reference Citation Analysis]
10 Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, Kudo M. Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomography. Hepatol Res 2017;47:E113-9. [PMID: 27138382 DOI: 10.1111/hepr.12735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtländer T, Wacker F, Manns MP, Rodt T, Vogel A. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol 2017;52:116-24. [PMID: 27598949 DOI: 10.1080/00365521.2016.1233579] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Moon H, Choi JE, Lee IJ, Kim TH, Kim SH, Ko YH, Kim HB, Nam BH, Park JW. All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. J Cancer Res Clin Oncol 2017;143:2327-39. [PMID: 28744575 DOI: 10.1007/s00432-017-2480-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Lucatelli P, Corona M, Argirò R, Anzidei M, Vallati G, Fanelli F, Bezzi M, Catalano C. Impact of 3D Rotational Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol 2015;38:523-35. [PMID: 25488820 DOI: 10.1007/s00270-014-1023-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
15 Wu FH, Shen CH, Luo SC, Hwang JI, Chao WS, Yeh HZ, Jan YG, Yen Y, Cheng SB, Wu CC, Lin YL, P'eng FK. Liver resection for hepatocellular carcinoma in oldest old patients. World J Surg Oncol 2019;17:1. [PMID: 30606220 DOI: 10.1186/s12957-018-1541-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
16 Zhang Y, Qu S, Yi W, Zhai J, Zhang X, Wei L, Lau WY, Wu M, Shen F, Fan H, Wu D. A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819844488. [PMID: 31204599 DOI: 10.1177/1533033819844488] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y. Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1272-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol 2019;54:905-12. [PMID: 31287338 DOI: 10.1080/00365521.2019.1632925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
21 Dasse KD, Lander MJ, Novelli PM. Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. J Adv Pract Oncol 2016;7:764-78. [PMID: 29670812 DOI: 10.6004/jadpro.2016.7.7.8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chen L, Ni C, Chen S, Cao J, Zhu H, Guo J, Zhu G, Zhong B, Ding W, He S, Deng G, Teng G. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. Journal of Vascular and Interventional Radiology 2016;27:1288-97. [DOI: 10.1016/j.jvir.2015.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
25 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
26 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 656] [Article Influence: 165.3] [Reference Citation Analysis]
27 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
28 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 2017;8:378-87. [PMID: 28261338 DOI: 10.7150/jca.16786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Wu J, Bai W, Han G, Fan D. ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: Is it really applicable? Journal of Hepatology 2014;61:176-7. [DOI: 10.1016/j.jhep.2014.02.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3:37-46. [PMID: 28988687 DOI: 10.1016/s2468-1253(17)30290-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
31 Kim HD, An J, Kim JH, Gwon DI, Shin JH, Ko GY, Yoon HK, Sung KB, Kim KM, Lee HC. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol 2016;27:504-13. [PMID: 26896049 DOI: 10.1016/j.jvir.2015.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
33 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 111] [Article Influence: 19.7] [Reference Citation Analysis]
34 Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-66. [PMID: 28488104 DOI: 10.1007/s00270-017-1681-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
35 Lin HC, Yang YS, Teng CJ, Shen CH, Jan YG, Cheng SB, Wu CC, Lin YL, Huang CC, P'eng FK. Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World J Surg Oncol 2017;15:194. [PMID: 29096656 DOI: 10.1186/s12957-017-1260-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. J Vasc Interv Radiol 2016;27:1829-36. [PMID: 27553917 DOI: 10.1016/j.jvir.2016.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
37 Wu CC, Shen CH, Liu HT, Lai CY, Cheng SB, Yu CC, Wang J, Yeh DC, P'eng FK. Unroofing hepatectomy: a facilitating approach for resection of deep-seated hepatocellular carcinoma adjacent to major intrahepatic vessels in cirrhotic patients. J Surg Oncol 2015;111:396-403. [PMID: 25720834 DOI: 10.1002/jso.23859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
38 Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016;279:630-640. [PMID: 26744927 DOI: 10.1148/radiol.2015150667] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
39 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
40 Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, Rashed NA, Ibrahim MM, Abdelmaksoud AH. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50:479-484. [PMID: 25592058 DOI: 10.3109/00365521.2014.1003397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
41 Ha Y, Lee JB, Shim JH, Kim KM, Lim YS, Yoon HK, Shin YM, Lee HC. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. Eur Radiol 2016;26:3510-8. [PMID: 26747261 DOI: 10.1007/s00330-015-4185-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Tseng CL, Lai WJ, Huang CJ, Huang YH, Su CW, Lee IC, Tseng HS, Li CP, Lee RC, Lin HC, Chao Y. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. Medicine (Baltimore) 2015;94:e1659. [PMID: 26632677 DOI: 10.1097/MD.0000000000001659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]